Journal ArticleDOI
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Reads0
Chats0
TLDR
Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.About:
This article is published in The Lancet.The article was published on 2019-07-13. It has received 1449 citations till now. The article focuses on the topics: Dulaglutide & Placebo-controlled study.read more
Citations
More filters
Journal ArticleDOI
Premature Death in Kidney Transplant Recipients: The Time for Trials is Now
TL;DR: The development of better immunosuppressive drugs, antivirals, and patient care protocols, short-term outcomes have improved. as mentioned in this paper showed that kidney transplant improves survival and quality of life, and reduces health care costs compared with maintenance dialysis.
Journal ArticleDOI
Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
TL;DR: The nephroprotective properties of dual GIP and GLP-1 receptor agonists as a new drug to treat type 2 diabetes are presented and preliminary results suggest that tirzepatide improves kidney outcomes in adults with type 1 diabetes with increased cardiovascular risk.
Journal ArticleDOI
Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States
TL;DR: The use of GLP-1 RAs and SGLT2 inhibitors increased during the study period; however, most patients did not receive these medications and patients aged ≥65 years were particularly disadvantaged.
Journal ArticleDOI
Evidence-based comparison of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors.
TL;DR: In vitro and animal studies have demonstrated that hyperglycemia elicits harmful effects on the cells that comprise the vasculature or those that are involved in the progression of atherosclerosis through various mechanisms such increased oxidative stress, advanced glycation end-product signaling, and protein kinase C activation.
Journal ArticleDOI
Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy
Daniel G. Dauner,Joel F. Farley +1 more
TL;DR: In this paper, the SUSTAIN-6 trial showed significantly higher rates of retinopathy complications in the semaglutide group compared to placebo compared to the placebo group.
References
More filters
Journal ArticleDOI
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
TL;DR: The purpose of this study was to develop an equation from MDRD Study data that could improve the prediction of GFR from serum creatinine concentration, and major clinical decisions in general medicine, geriatrics, and oncology are made by using the Cockcroft-Gault formula and other formulas to predict the level of renal function.
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
TL;DR: The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal ArticleDOI
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.
Andrew S. Levey,Josef Coresh,Tom Greene,Lesley A. Stevens,Yaping (Lucy) Zhang,Stephen Hendriksen,John W. Kusek,Frederick Van Lente +7 more
TL;DR: The MDRD Study equation has now been reexpressed for use with a standardized serum creatinine assay, allowing GFR estimates to be reported in clinical practice by using standardized serumcreatinine and overcoming this limitation to the current use of GFR estimating equations.
Journal ArticleDOI
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown-Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse +14 more
TL;DR: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, orNonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.